CBD shows biological promise for nausea, but current evidence does not support off-the-shelf CBD products as a reliable standalone treatment: the strongest clinical results come from specialist THC:CBD regimens used alongside guideline antiemetics for chemotherapy-related nausea. If you are on regular medication, pregnant or breastfeeding, or dealing with persistent nausea, speak to a clinician before trying any CBD product. The sections below walk through the human trial data, the underlying mechanisms, and the safety context you need.
TL;DR:
- Most human research showing nausea relief involves THC or synthetic cannabinoids, not over-the-counter CBD products; clinical benefits for CBD-only are limited.
- The strongest evidence comes from specialist THC:CBD combinations used with standard antiemetics in refractory chemotherapy-induced nausea, not routine use.
- Preclinical studies suggest CBD and CBDA reduce nausea via serotonin receptor activation, but effective human doses and formulations are unproven.
- The UK’s safety limit for CBD is 10 mg daily for food use, which may not be sufficient for therapeutic effects and carries certain risks, especially for vulnerable groups.
- Practical use should start with low doses, avoid combining with alcohol or driving, and involve checking lab analysis to ensure product purity and accurate cannabinoid content.
Table of Contents
- What the research in humans actually shows about CBD and nausea
- How CBD and CBDA might reduce nausea: mechanisms from preclinical work
- Safety, interactions and the UK’s provisional ADI for CBD
- Practical guidance if you decide to try a CBD product for mild nausea
- When to see a doctor, and how cannabinoids fit into medical nausea care
- Our take: plausible, not proven, and worth saying so plainly
- SMOKO CBD’s product range for a cautious, informed trial
- FAQ
- Sources
What the research in humans actually shows about CBD and nausea
The honest answer is that we have more mechanistic plausibility than proof. Most of the positive human data involves cannabinoid medicines that contain THC, not the broad-spectrum CBD products sold over the counter, and that distinction matters for anyone trying to interpret the headlines.
A 2025 systematic review looking at cannabinoids for chemotherapy-induced nausea and vomiting pooled data from 32 studies covering 1,889 patients and found a pooled relative risk of 2.65 (95% CI 1.70 to 4.12) favouring cannabinoids over placebo for complete control of vomiting, according to a systematic review of cannabinoids for chemotherapy-related nausea. That sounds compelling until you look at what made up those 32 studies: many were older trials using cannabinoid regimens compared against outdated antiemetics, not the modern guideline-based combinations oncologists use today. The review’s own conclusion was that evidence remains insufficient to recommend cannabinoids as a routine replacement for current standard care, even though the signal versus placebo is real.
A phase II/III trial found a THC:CBD extract roughly tripled complete response rates in refractory chemotherapy nausea when added to guideline antiemetics, according to a phase II/III trial of oral THC:CBD extract, rising from 8% to 24% among 147 evaluable participants dosed at 2.5 mg THC plus 2.5 mg CBD three times daily. That is a meaningful result for people whose nausea has not responded to standard treatment, and it is the kind of data that keeps cannabinoids on the oncology radar. It is also a result built entirely around a 1:1 THC:CBD formulation taken under medical supervision, not a CBD-only tincture or gummy bought online.
Several points are worth holding onto when you read coverage of “CBD and nausea” research:
- Positive trials almost always involve THC-containing or synthetic cannabinoid medicines (dronabinol, nabilone, nabiximols), not CBD-only products, as the clinical cannabinoid literature on approved medicines makes clear.
- The 2024 THC:CBD trial reported sedation in 18% of participants versus 7% on placebo, and dizziness in 10% versus 0%, so the benefit came with a tangible side-effect cost.
- Robust trials testing CBD alone, at consumer-relevant doses, for ordinary everyday nausea (rather than chemotherapy) are scarce. Most encouraging findings for isolated CBD come from animal studies rather than human trials.
- Trial formulations vary widely in cannabinoid ratio, dose and delivery method, which makes it hard to generalise from one study to an unrelated product on a shop shelf.
None of this means CBD does nothing for nausea. It means the clearest clinical wins involve THC, supervision and refractory cases, while everyday CBD-only use rests mainly on mechanistic reasoning and smaller preclinical studies rather than large human trials.
How CBD and CBDA might reduce nausea: mechanisms from preclinical work
The biological case for CBD and nausea is genuinely interesting, and it starts with a receptor most people have never heard of outside a biology lecture: 5-HT1A.
Animal studies suggest that CBD and its acidic precursor CBDA reduce nausea-like behaviour largely by activating 5-HT1A receptors, a serotonin receptor subtype involved in regulating the body’s vomiting and nausea circuitry, according to a preclinical review on CBD, CBDA and CBDA-ME for nausea. This is a different route from how THC works. THC primarily acts on CB1 receptors, the same receptor system responsible for the “high” associated with cannabis, and that CB1 activity is thought to drive THC’s own antiemetic effect, as well as some of its psychoactive side effects. CBD interacts with CB1 only weakly, which is part of why it does not produce intoxication, but also why its anti-nausea mechanism looks fundamentally different.
One of the more striking findings in the preclinical literature is that CBDA, and a related synthetic compound called CBDA-ME, appear considerably more potent than CBD itself at reducing nausea responses in animal models, with effects detectable at doses roughly 1,000 times lower than CBD in some experiments described in research on cannabinoid regulation of nausea and vomiting. That is a notable translational gap: the compound showing the most promise in the lab, CBDA, is rarely present in meaningful amounts in the broad-spectrum tinctures, gummies and capsules sold to consumers, which are formulated around CBD rather than its acidic precursor.
A few mechanistic points worth keeping in mind:
- 5-HT1A receptor activation is the leading proposed pathway for CBD and CBDA’s anti-nausea effects in shrew and rat models of nausea-like behaviour.
- CB1 receptor engagement explains much of THC’s antiemetic action but is not the primary route for CBD, which helps explain why the two cannabinoids behave differently in trials.
- CBDA and CBDA-ME show greater potency than CBD in preclinical models, but neither is a standardised ingredient in typical consumer CBD products.
- Some animal studies show a biphasic dose response: low doses reduce nausea-like behaviour, while higher doses can lose effectiveness or even worsen the response in certain models, a pattern that complicates simple “more is better” dosing logic.
This is a case where the laboratory story is more convincing than the real-world product story. The receptor mechanisms are plausible and reasonably well mapped in animals, but translating that into a dependable human dose for everyday nausea has not yet happened in a way that supports strong claims.
Safety, interactions and the UK’s provisional ADI for CBD
Before trying any CBD product for nausea, it helps to understand where UK regulators have actually drawn a line, because it is narrower than most marketing suggests.
The Food Standards Agency has considered a provisional acceptable daily intake of 10 mg of CBD per day for a healthy adult, based on a joint assessment from the Advisory Committee on Novel Foods and Novel Processes and the Committee on Toxicity, according to the FSA’s novel food safety assessment for CBD. It is worth being precise about what that figure actually is: a food-safety benchmark for novel-food products containing high-purity CBD isolate, not a clinically validated dose for treating nausea or any other condition. Many consumer products, including flavoured gummies and tinctures, deliver more than 10 mg per serving, which is one reason the FSA’s own guidance points vulnerable groups towards caution rather than routine use.
The same safety assessment flagged adverse effects reported in cannabinoid studies, including somnolence and dizziness, along with the possibility of CYP3A4 inhibition at higher intake levels, an enzyme pathway responsible for metabolising a large share of prescription medicines.
Pro Tip: If you take any regular prescription medicine, check with a pharmacist before adding CBD, since CYP3A4 interactions can quietly raise or lower the levels of other drugs in your blood.
A few groups carry extra risk and should treat CBD for nausea with particular caution:
- Pregnant or breastfeeding people, who the FSA and related guidance advise should avoid CBD products altogether given the lack of safety data in these groups.
- Children, whose developing systems have not been studied for routine CBD exposure in the way adult doses have.
- People who are immunosuppressed or managing complex chronic conditions, where unpredictable interactions carry a higher stake.
- Anyone on regular prescription medication, particularly drugs metabolised via CYP3A4, such as certain blood thinners, antidepressants and immunosuppressants, where a pharmacist conversation is the sensible first step.
Sedation and dizziness are not abstract risks either. If a CBD product makes you drowsy or unsteady, driving, operating machinery or even standing up quickly can become genuinely hazardous, particularly for older adults where a fall carries larger consequences. There is no established, evidence-based “nausea dose” for CBD the way there is for, say, an antihistamine or an antiemetic tablet, so anyone starting out is working from safety limits rather than a proven therapeutic target. We cover the practical side of that gap, including how the FSA’s 10 mg figure interacts with real product labels, in our guide to the FSA’s 10 mg limit.
Practical guidance if you decide to try a CBD product for mild nausea
If you have read the evidence above and still want to try CBD for occasional, mild nausea rather than anything severe or persistent, a few practical choices make a genuine difference to how it feels in practice.
Different formats behave differently once they are in your system. Sublingual tinctures, held under the tongue for 60 to 90 seconds before swallowing, tend to act faster than capsules or gummies because some of the CBD is absorbed through the tissue under the tongue rather than relying entirely on digestion. Gummies and soft gel capsules pass through the digestive system first, which generally means a slower onset, often 45 minutes to two hours, but steadier, more predictable dosing from one serving to the next. Oromucosal sprays sit somewhere in between, offering a metered dose with relatively fast absorption through the mouth lining.
- Start at the lowest realistic dose your chosen product allows, note the time you took it and how you feel over the following two to three hours, rather than adjusting the amount before you have given it a chance to work.
- Avoid alcohol and driving in the hours after dosing, since combining CBD with alcohol can intensify drowsiness, and any sedative effect makes driving unsafe regardless of how mild it feels.
- Check the certificate of analysis before buying: confirm the CBD content per serving matches the label, check for a non-detect or clearly stated THC result, and look for a contaminant screen covering pesticides and heavy metals, with a batch number that ties the certificate to the exact product you hold, a step the FSA’s own safety assessment treats as a meaningful risk-reduction measure.
- Match the format to the problem. A rapid-onset sublingual tincture may suit occasional, transient nausea, such as before travel, better than a gummy that takes an hour or more to act, while a consistent daily soft gel may suit someone tracking a steady background dose over several days rather than chasing a single episode.
- Reassess after a short trial period. If a few attempts bring no noticeable change, repeating the same dose for weeks on the assumption it will eventually work is not supported by the evidence and is a reasonable point to stop and speak to a clinician instead.
For anyone managing nausea alongside other age-related considerations, our practical guide to CBD tinctures for older adults covers dosing caution in more detail, and our piece on CBD and appetite walks through how the FSA’s intake limit plays out against typical product servings.
When to see a doctor, and how cannabinoids fit into medical nausea care
Self-trialling a CBD product only makes sense for mild, occasional nausea. Certain symptoms should send you to a GP or urgent care rather than to a product label.
Seek medical assessment promptly if nausea comes with any of the following:
- Signs of dehydration, such as reduced urination, dizziness on standing or a dry mouth that persists despite fluids.
- Vomiting that will not stop, or that has lasted more than 24 to 48 hours without improvement.
- Severe or worsening abdominal pain alongside the nausea.
- Pregnancy, where persistent nausea and vomiting need a clinician’s assessment rather than a self-managed trial of any supplement.
Nausea is a symptom, not a diagnosis, and treating the symptom with an unproven supplement while ignoring an underlying cause, whether that is an infection, a medication side effect or something more serious, carries its own risk. NHS and NICE guidance on cannabis-based products for medicinal use is clear that cannabinoids sit within specialist oncology and palliative pathways, used as an adjunct when standard guideline antiemetics have already failed, according to NHS guidance on cannabis-based medicinal products. That is a managed clinical decision involving prescribed, often THC-containing, medicines under supervision, not a suggestion that over-the-counter CBD can substitute for prescribed antiemetics in chemotherapy or any other serious nausea context. If you are undergoing treatment that causes nausea, the right conversation is with your oncology team, not a product review.
Our take: plausible, not proven, and worth saying so plainly
CBD’s anti-nausea story is more convincing in a petri dish and a rodent model than it is in a human trial, and we think that gap deserves to be stated honestly rather than smoothed over with marketing language. The receptor science, particularly around 5-HT1A activation, gives CBD a genuine biological reason to help with nausea. What is missing is a body of large, well-designed human trials testing CBD alone, at realistic consumer doses, against ordinary everyday nausea rather than chemotherapy-related vomiting treated under medical supervision.
That does not make CBD worthless for this use. It makes it an option some people may reasonably try for mild, occasional symptoms, provided they understand they are working from plausibility rather than proof, and provided anyone on medication or dealing with persistent symptoms talks to a clinician first. We would rather a reader walk away cautious and well-informed than convinced by a claim the evidence cannot yet support.
Where we can speak with more certainty is on product quality. Broad-spectrum CBD verified by third-party lab testing, with a clear certificate of analysis showing cannabinoid content and a non-detect THC result, removes one major source of uncertainty from an already uncertain picture. That will not turn CBD into a proven antiemetic, but it does mean you know what you are actually taking.
— Mike
SMOKO CBD’s product range for a cautious, informed trial
If you have weighed the evidence above and want to try CBD for mild, occasional nausea, our range is built around the same principles this article has covered: know your dose, check your lab report, and start low.
We sell three formats, and each suits a slightly different approach. Our CBD Tinctures give you the most control over dose, since you can adjust drops to find your own starting point and they tend to act faster when held under the tongue. Our CBD Gummy Bears offer a fixed, convenient serving with no measuring involved, useful if you would rather not think about dosing once you have settled on an amount, such as our 250mg broad-spectrum gummy pack. Our CBD Soft Gels deliver the same consistent dose capsule after capsule, which some readers prefer for tracking intake over several days.
Every product we sell is broad-spectrum, made from organically grown hemp, and verified THC-free through third-party lab testing, so you can check the certificate of analysis against the batch number on your product before you take anything. If you are unsure which format fits your situation, our customer support team can talk you through the practical differences.
| Product line | Format | What it suits |
|---|---|---|
| CBD Tinctures | Sublingual drops | Flexible dosing, faster onset |
| CBD Gummy Bears | Edible, fixed dose | Convenience, no measuring |
| CBD Soft Gels | Capsule, fixed dose | Consistent daily intake |
Browse our full CBD tinctures, gummy bears and soft gels and start with the lowest serving size on the label.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
FAQ
Does CBD calm an upset stomach?
CBD may have a mild calming effect on nausea for some people through its interaction with serotonin receptors, but human evidence specifically for an upset stomach is limited. Most of the supportive data comes from animal studies and from THC-containing cannabinoid medicines used in chemotherapy settings, not from CBD-only products tested against everyday stomach upset.
What gets rid of nausea fast?
Fast, evidence-backed relief for nausea typically involves addressing the underlying cause (dehydration, motion, infection) alongside measures such as sipping clear fluids, resting, and using over-the-counter or prescribed antiemetics where appropriate. CBD has not been established as a fast-acting nausea remedy in human trials, so it should not replace proven antiemetic approaches for acute or severe symptoms.
Are there any CBD gummies that can help with nausea?
CBD gummies have not been tested in large human trials specifically for nausea, so no gummy can be said to reliably treat it. Our broad-spectrum CBD gummy bears offer a fixed, lab-tested dose if you want to try a convenient format for mild, occasional symptoms, with the same caution that applies to any CBD product.
Which CBD product is best for nausea and anxiety?
No single CBD format is proven best for nausea, and the clinical evidence for anxiety is separate from the nausea evidence covered here. A sublingual tincture offers more dosing flexibility and a faster onset, which some people find useful for trying a low starting dose and adjusting gradually under their own observation.
Sources
- Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting
- Cannabinoids for the prevention of chemotherapy-induced nausea and vomiting in oncological therapy: a systematic review
- Phase II/III trial of an oral THC:CBD extract as adjunctive therapy for chemotherapy-induced nausea and vomiting
- Safety assessment of cannabidiol (CBD) as a novel food for use in food and food supplements (RP521)
- NHS long-read: cannabis-based products for medicinal use (overview)
